HC Wainwright Expects Higher Earnings for Zevra Therapeutics

Key Points

• HC Wainwright revised its Q3 2025 earnings per share estimate for Zevra Therapeutics from (0.07) to (0.06) and maintains a "Buy" rating with a price target of $26.00.
• Zevra Therapeutics reported a Q2 loss of (0.06) EPS, significantly missing the expected $1.43 EPS, while revenues exceeded expectations at $25.88 million.
• The stock currently has a consensus "Buy" rating from nine analysts and an average price target of $23.71, indicating positive market sentiment despite recent rating changes.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - HC Wainwright lifted their Q3 2025 EPS estimates for Zevra Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.06) per share for the quarter, up from their previous estimate of ($0.07). HC Wainwright has a "Buy" rating and a $26.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics' Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at $1.14 EPS and FY2028 earnings at $2.42 EPS.

Several other equities analysts have also recently issued reports on ZVRA. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Zacks Research downgraded Zevra Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday. Cantor Fitzgerald increased their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Wall Street Zen downgraded shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. Finally, JMP Securities reduced their price target on shares of Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating on the stock in a report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Price Performance

Shares of ZVRA traded up $0.27 on Friday, reaching $9.28. The stock had a trading volume of 430,788 shares, compared to its average volume of 732,120. The firm has a market capitalization of $520.93 million, a PE ratio of -44.19 and a beta of 1.87. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52. The firm has a 50-day moving average of $10.55 and a 200 day moving average of $8.78. Zevra Therapeutics has a twelve month low of $6.19 and a twelve month high of $13.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in Zevra Therapeutics by 50.5% during the fourth quarter. JPMorgan Chase & Co. now owns 27,490 shares of the company's stock worth $229,000 after purchasing an additional 9,225 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Zevra Therapeutics by 13.8% during the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company's stock worth $9,912,000 after buying an additional 144,256 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Zevra Therapeutics by 65.4% in the 4th quarter. Wells Fargo & Company MN now owns 29,701 shares of the company's stock worth $248,000 after buying an additional 11,744 shares during the period. Invesco Ltd. boosted its holdings in Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after acquiring an additional 3,007 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Zevra Therapeutics during the fourth quarter worth about $224,000. Institutional investors and hedge funds own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.